CHARACTERIZATION OF STERILE INTRAOCULAR INFLAMMATORY RESPONSES AFTER INTRAVITREAL BEVACIZUMAB INJECTION
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this study was to determine the frequency and characteristics of sterile intraocular inflammation occurring after intravitreal bevacizumab (IVB) (Avastin, Genentech, South San Francisco, CA) injection and to analyze whether a repeat IVB or intravitreal ranibizumab (IVR) (Lucentis, Genentech) injection after an episode of postinjection inflammation elicits a repeat inflammatory reaction. METHODS: A retrospective case series evaluated 16,166 IVB injections administered between 2006 and 2008. Patients with postinjection inflammation were analyzed for the number of previous injections, time from prior injection to incident injection, presenting signs and symptoms, treatment, visual acuity, time from onset to resolution and recovery of vision, and whether repeat injection caused recurrent inflammation. RESULTS: The incidence of sterile intraocular inflammation after IVB injection resolving with topical antibiotics and steroids alone was 0.27% (44 of 16,166). The average number of prior IVB injections in the ipsilateral eye was 2.8 ± 0.4 with 10 cases occurring with first-time injections. The average time from injection to recovery of visual acuity was 53 ± 18 days, and from injection to resolution of inflammation was 37 ± 5 days. Thirty-six cases received subsequent IVB or intravitreal ranibizumab, and there were three episodes of recurrent inflammation with repeat IVB. The average follow-up was 17 ± 1 month. CONCLUSION: In most cases of sterile intraocular inflammation after IVB, visual acuity returned to baseline, and intraocular inflammation rarely recurred with repeat IVB or intravitreal ranibizumab.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, patients may theoretically be more prone to inflammation when breakdown of the blood-retina barrier occurs in certain conditions such as exudative AMD, compromising the immune privilege of the vitreous [44].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [44]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Structure-Immunogenicity Relationships of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617 · cited 3×
“A patient’s major histocompatibility complex genotype may also influence the propensity to develop an immune reaction against certain monoclonal antibodies.(10)”
BackgroundInfluentialFung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
FINTAK, D. R., SHAH, G. K., BLINDER, K. J., REGILLO, C. D., POLLACK, J., HEIER, J. S., HOLLANDS, H., & SHARMA, S. (2008) · Retina · doi:10.1097/iae.0b013e3181884fd2 · Cited by 214 · cited 5×
“After 1 episode of sterile intraocular inflammation after IVB, 48% of the cases received repeat IVB, and 48% received subsequent IVR.”
BackgroundInfluentialPilli, S., Kotsolis, A., Spaide, R. F., Slakter, J., Freund, K. B., Sorenson, J., Klancnik, J., & Cooney, M. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.036 · Cited by 181 · cited 1×
“intravitreal antibiotics without performing a culture to prove an infectious etiology.(4,5) Other cases of culturenegative endophthalmitis resolve without intravitreal antibiotics and represent sterile noninfectious inflammation; the reported incidence of these is 0.”
BackgroundBrooks, S. A. (2004) · Molecular Biotechnology · doi:10.1385/mb:28:3:241 · Cited by 165 · cited 1×
“Additionally, bevacizumab is synthesized in a Chinese hamster ovarian cell line, and because glycosylation is species-and cellspecific, recombinant glycoproteins such as bevacizumab may have immunogenic epitopes despite humanized amino acid sequences.(8,12) Foreign epitopes on the bevacizumab molecule can be presented…”
BackgroundIntravitreal Silicone Oil Droplets After Intravitreal Drug Injections
Bakri, S. J., & Ekdawi, N. S. (2008) · Retina · doi:10.1097/iae.0b013e31816c6868 · Cited by 128 · cited 1×
“Silicone oil droplets have been documented in the vitreous after IVB and IVR, but have not been associated with intraocular inflammation.(14)”
BackgroundWickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124 · cited 2×
“An antiidiotypic immune response should occur with increasing severity with each rechallenge.(7,15) However, in the 2 patients (patient 14 and patient 43) who developed recurrent inflammation after repeat IVB, the subsequent inflammatory reactions tended to be more vigorous, suggesting that in most patients, a specifi…”
Background
Cited by
Diagnostic and Therapeutic Challenges
Sadiq, M. A., Loh, G. K., Sepah, Y. J., Nguyen, Q. D., & Lin, P. (2015) · Retina · doi:10.1097/iae.0000000000000275 · Cited by 217
Zhao, Y., & Singh, R. P. (2018) · Drugs in Context · doi:10.7573/dic.212532 · Cited by 191
Endophthalmitis: state of the art
Schwartz, S., Vaziri, K., Kishor, K., & Flynn, Jr. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s76406 · Cited by 164
Where should siRNAs go: applicable organs for siRNA drugs
Ahn, I., Kang, C. S., & Han, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00998-y · Cited by 171
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Inflammatory Complications of Intravitreal Anti-VEGF Injections
Cox, J. T., Eliott, D., & Sobrin, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050981 · Cited by 137
“demonstrated mean visual acuities of 20/114 at injection, 20/425 at presentation, and 20/143 at the last follow up [33].”
BackgroundInfluentialDaïen, V., Nguyen, V., Essex, R. W., Morlet, N., Barthelmes, D., Gillies, M. C., Gillies, M. C., Hunt, A., Essex, R. W., Dayajeewa, C., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.07.005 · Cited by 110
Zehden, J., Mortensen, X. M., Reddy, A. K., & Zhang, A. Y. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01491-y · Cited by 95
London, N. J. S., Garg, S. J., Moorthy, R. S., & Cunningham, E. T. (2013) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/1869-5760-3-43 · Cited by 97
“Despite an otherwise relatively strong safety profile in several large, multicenter studies, there have been several reports of uveitis associated with intraocular injection of these medications [130,144-153].”
Vitreous Inflammation Associated with Intravitreal Anti-VEGF Pharmacotherapy
Agrawal, S., Joshi, M., & Christoforidis, J. B. (2013) · Mediators of Inflammation · doi:10.1155/2013/943409 · Cited by 83
“Also, in order to avoid confusion, only the studies reporting noninfectious endophthalmitis were included.”
BackgroundAflibercept-Related Sterile Inflammation
Hahn, P., Kim, J. E., Stinnett, S., Chung, M. M., Dugel, P. U., Flynn, H. W., Huang, S. S., Sadda, S. R., & Mahmoud, T. H. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.018 · Cited by 74
“Orthokeratology involves using reverse-geometry, rigid, gas-permeable contact lenses to reduce manifest refractive error.(4) In myopic orthokeratology, the central zone of the lens imparts a positive hydraulic pressure to induce corneal flattening; the epithelium is compressed such that basal cells assume a rounded co…”
BackgroundRate of serious adverse effects in a series of bevacizumab and ranibizumab injections
Sharma, S., Johnson, D. E., Abouammoh, M. A., Hollands, S., & Brissette, A. R. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.03.026 · Cited by 80
Williams, P. D., Chong, D., Fuller, T., & Callanan, D. (2016) · Retina · doi:10.1097/iae.0000000000000801 · Cited by 69
“The results from this initial search were previously published, and these patients were used as a subset for this study.(2) From 2009 to 2013, billing records were used to search electronic medical records for all encounters occurring within 7 days of injection of bevacizumab, ranibizumab, or aflibercept.”
MethodSelf-citationAflibercept-Related Sterile Intraocular Inflammation Outcomes
Greenberg, J. P., Belin, P., Butler, J., Feiler, D., Mueller, C., Tye, A., Friedlander, S. M., Emerson, G. G., & Ferrone, P. J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.04.006 · Cited by 69
Wang, E., & Chen, Y. (2013) · Retina · doi:10.1097/iae.0b013e31827d260a · Cited by 69
Sterile Endophthalmitis after Intravitreal Injections
Marticorena, J., Romano, V., & Gómez-Ulla, F. (2012) · Mediators of Inflammation · doi:10.1155/2012/928123 · Cited by 65
“Different authors have highlighted the presence of sterile endophthalmitis after repeated intravitreal bevacizumab injections [40, 43].”
BackgroundNeonatal Endogenous Endophthalmitis: A Report of Six Cases
Basu, S., Kumar, A., Kapoor, K., Bagri, N. K., & Chandra, A. (2013) · PEDIATRICS · doi:10.1542/peds.2011-3391 · Cited by 52
Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration
Abouammoh, M. A., & Sharma, S. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834595d0 · Cited by 42
FREQUENCY AND CHARACTERISTICS OF INTRAOCULAR INFLAMMATION AFTER AFLIBERCEPT INJECTION
Fine, H. F., Roth, D. B., Shah, S. P., Haque, T., & Wheatley, H. M. (2015) · Retina · doi:10.1097/iae.0000000000000398 · Cited by 37
“Finally, although bevacizumab is a humanized antibody, its synthesis in Chinese hamster ovary cells may introduce nonhuman glycosylation that could be immunogenic.(17) The exact mechanism underlying inflammation after aflibercept injection remains unknown, but certainly the factors implicated for bevacizumab might be…”
BackgroundOcular inflammation associated with antivascular endothelial growth factor treatment
Fine, H. F., Despotidis, G. D., & Prenner, J. L. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000154 · Cited by 35
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
Hoffmann, L., Michels, S., Eandi, C. M., Karam, M. A., Figueiredo, E. C. D. O., & Hatz, K. B. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03788-w · Cited by 35
“A history of prior intravitreal anti-VEGF injections has not been shown to increase the risk of IOI with subsequent injections [19].”
Johnson, D. E., & Sharma, S. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835f8ec0 · Cited by 36
Extended release of dexamethasone from oleogel based rods
Macoon, R., Guerriero, T., & Chauhan, A. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.07.082 · Cited by 28
Singh, R., Davoudi, S., & Ness, S. D. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05607-8 · Cited by 35
Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD
Khoramnia, R., Figueroa, M. S., Kuhli-Hattenbach, C., Pavesio, C. E., Anderesi, M., Schmouder, R., Chen, Y., & de Smet, M. D. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05518-0 · Cited by 25
Signorello, L., Pucciarelli, S., Bonacucina, G., Polzonetti, V., Cespi, M., Perinelli, D. R., Palmieri, G. F., Pettinari, R., Pettinari, C., Fiorentini, G., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140619120834 · Cited by 28
“The surgical techniques and characteristics of the administered drug determine the safety profile of intravitreal injections, in fact one of the most relevant and upsetting complications is endophthalmitis [19, 20].”
BackgroundAcute sterile endophthalmitis following intravitreal bevacizumab: case series
Vélez-Montoya, R., Ortega-Larrocea, X., Orozco‐Hernández, A., Sánchez-Bermúdez, G., Morales-Cantón, V., & García‐Aguirre, G. (2014) · Clinical ophthalmology · doi:10.2147/opth.s66230 · Cited by 25
“Certain intravitreal drugs can produce an acute and sterile intraocular inflammation that can mimic infectious endophthalmitis.(4,18,24,25) An accurate differential between these two entities is crucial, as a delay in treatment of the former or unnecessary treatment of the latter can have major consequences.”
Whiting, R. E. H., Kick, G. R., Ota‐Kuroki, J., Lim, S., Castaner, L. J., Jensen, C. A., Kowal, J. B., Nguyen, A., Corado, C. R., O’neill, C. A., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108135 · Cited by 23
Dolar-Szczasny, J., Bucolo, C., Zweifel, S. A., Carnevali, A., Ręjdak, R., Załuska, W., Czarnek-Chudzik, A., & Toro, M. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656774 · Cited by 16
Blaha, G. R., Brooks, N. O., Mackel, C. E., Pani, A., Stewart, A. P., Price, L. L., Barouch, F. C., Chang, J., & Marx, J. L. (2014) · Retina · doi:10.1097/iae.0000000000000334 · Cited by 13
Callanan, D., Khurana, R. N., Maturi, R. K., Patel, S. S., Wykoff, C. C., Eichenbaum, D. A., Khanani, A. M., Hassan, T., Badger, H., Mehta, S., et al. (2023) · Clinical ophthalmology · doi:10.2147/opth.s405994 · Cited by 13
Self-citationTRANSVITREAL FIBRINOID PSEUDOENDOPHTHALMITIS AFTER DIABETIC VITRECTOMY
Luo, C., Ruby, A. J., Neuwelt, M. D., & Williams, G. A. (2013) · Retina · doi:10.1097/iae.0b013e31828abe67 · Cited by 12
Current intravitreal pharmacologic therapies for diabetic macular edema
Colucciello, M. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1052523 · Cited by 13
“This is generally responsive to topical steroid agents [99-104].”
BackgroundHautamäki, A., Luoma, A., & Immonen, I. (2016) · Retina · doi:10.1097/iae.0000000000001061 · Cited by 11
STERILE ENDOPHTHALMITIS AFTER INTRAVITREAL OCRIPLASMIN INJECTION
Han, I. C., & Scott, A. W. (2015) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000149 · Cited by 10
Demirel, S., Bilici, S., Batıoğlu, F., & Özmert, E. (2016) · Ophthalmic Research · doi:10.1159/000444497 · Cited by 10
Delayed onset panuveitis following intravitreal aflibercept injection
Glading, J. A., Lake, S. R., Craig, J. E., & Supramaniam, D. (2014) · BMJ Case Reports · doi:10.1136/bcr-2013-202515 · Cited by 9
Vaughan, M., Denmead, P., Tay, N., Rajendram, R., Michaelides, M., & Patterson, E. J. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06828-3 · Cited by 9
“Although anti-VEGF treatment can be highly effective in some patients [31], others do not respond to the intra-ocular injections [32–34].”
Astakhov, Y. S., Belekhova, S. G., & Litvinova, E. A. (2017) · Ophthalmology Reports · doi:10.17816/ov10162-69 · Cited by 12
Bagheri, S., Ntentakis, D. P., Emfietzoglou, M., Ashourizadeh, H., Grinspan, N., Ploumi, I., Armstrong, G. W., & Miller, J. B. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000580 · Cited by 7
Hoffmann, L., & Hatz, K. B. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01349-6 · Cited by 6
“Like-wise, in previous studies, the history of pretreatment with anti-VEGF agents was not linked to an increased risk of IOI with subsequent injections [17].”
InfluentialClinical Course and Characteristics of Eyes with Recurrent Episodes of Endophthalmitis
Shields, R. A., Lee, I. J., Brown, M. M., Dong, L. K., Lee, R., Wa, C. A., & Hassan, T. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.06.011 · Cited by 6
Uzun, A., Yalçındağ, F. N., Demirel, S., Batýoðlu, F., & Özmert, E. (2016) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2015.1108445 · Cited by 6
“tion following bevacizumab injection was greater than with ranibizumab injection, and suggested that the full-length molecule of bevacizumab containing both of Fab and Fc fragments and/or manufacturing and preparation of the drug could induce its immunologic effect.(12).”
BackgroundModern diagnosis and treatment of endophthalmitis
Khalatyan, A. S. (2020) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2020136042258 · Cited by 4
Sterile Intraocular Inflammation After Intravitreal Injection—Diagnosis and Management
Greenberg, J. P., Peiris, T. J., & Lieberman, R. M. (2019) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2019.04.010 · Cited by 4
Outcomes and Practice Preferences After Endophthalmitis Following Anti-VEGF Intravitreal Injection
Chen, Y., Shah, G. K., Shah, V., Blinder, K. J., Jeroudi, A. M., Leonard, A. P., Gilca, M., Pollack, J. S., Wang, R., Wykoff, C. C., et al. (2019) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126419858492 · Cited by 4
“6822 20/40 or better final VA 159 (n 1⁄4 27) (21-742) Culture positive 116 (n 1⁄4 10) Culture negative 210 (n 1⁄4 12) P 1⁄4 .”
Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China
Huang, H., Pan, Y., & Liu, T. (2013) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2012.00812.x · Cited by 4
Desideri, L. F., Fukuhara, P. S., Wintergerst, M. W. M., Meyer, C. H., Emerson, G. G., Anguita, R., & Melo, G. B. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.02.005 · Cited by 3
Hamichi, S. E., Aguilar, R. J., Graversen, V. K., Gold, A. S., Berrocal, A. M., & Murray, T. G. (2020) · Case Reports in Ophthalmology · doi:10.1159/000508390 · Cited by 3
Kuriyan, A. E., Hussain, R. M., & Flynn, H. W. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_98 · Cited by 3
Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents
Iyer, P. G., & Albini, T. A. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000438 · Cited by 3
Montolío-Marzo, S., Oliver, L. V., Montolío‐Marzo, E., Dolz‐Marco, R., & Gallego‐Pinazo, R. (2023) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2023.04.004 · Cited by 3
Montolío-Marzo, S., Oliver, L. V., Montolío‐Marzo, E., Dolz‐Marco, R., & Gallego-Pinazo, R. (2023) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2023.04.014 · Cited by 3
Mizukami, T., Ueno, S., Mishima, S., & Shimomura, Y. (2025) · Biologics · doi:10.3390/biologics5030025 · Cited by 2
Pharmacokinetic model for drug delivery by Ozurdex
Kumara, B. N., Dey, A., Kompella, U. B., & Chauhan, A. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02029-x · Cited by 2
“Such frequent injections increase patient discomfort, while also increasing cost and the possibility of infection or other more serious complications such as retinal detachment [26–29].”
Kıvrak, U., Arsan, A. K., Akçay, G., Bulut, M. N., Kanar, H. S., Hacısalihoğlu, A., & Şimşek, Ş. (2024) · International Ophthalmology · doi:10.1007/s10792-024-03134-5 · Cited by 3
“Similar to other studies, the visual acuity of the patients in this case series initially decreased compared to the preinjection level but returned to the pre-injection level in an average of one month after the regression of inflammation [26, 28].”
InfluentialIntravitreal Aflibercept after Bilateral Bevacizumab‐Induced Iritis
Skorin, L., & Genereux, L. (2015) · Optometry and Vision Science · doi:10.1097/opx.0000000000000568 · Cited by 2
“These reports fall in line with the claim by Chong et al.(16) that if indeed inflammation in bevacizumab patients is attributed to a specific immune response to the bevacizumab drug, there is no cross-reactivity with ranibizumab.”
ResultPost-traumatic Uveitis and Post-operative Inflammation
Barb, S. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-09126-6_40 · Cited by 2
Areas of uncertainty in endophthalmitis care
Venkatesh, R., Hande, P., James, E., Chokkahalli, N. K., Ranganath, P., Kathare, R., Prabhu, V., Jayadev, C., Tendulkar, K., Raj, P., et al. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i6.118263 · Cited by 1
“Evidence guiding rechallenge decisions is sparse, and risk stratification remains largely empirical[104].”
Diagnostic and Therapeutic Challenges
Moore, P. P., Matthews, B. J., Chiu, D., Chandra, A., & Quiram, P. A. (2016) · Retina · doi:10.1097/iae.0000000000000975 · Cited by 1
“Cases of pseudoendophthalmitis have been reported after injection of intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents.(1,2) Toxic anterior segment syndrome also can present with a noninfective hypopyon 24 to 72 hours after intraocular surgery.”
BackgroundPostprocedural Endophthalmitis or Postprocedural Intraocular Inflammation: A Diagnostic Conundrum
Busaidi, A. A., & Al-Hinai, A. (2021) · Case Reports in Ophthalmology · doi:10.1159/000511970 · Cited by 1
Intravitreal injection of avastin (Bevacizumab) from a single vial causing pseudo endophthamitis
Raj, K., & Sadiqulla, M. (2020) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.2020.116
Kuriyan, A. E., Hussain, R. M., & Flynn, H. W. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_98-1
(2014) · Journal of Ocular Biology · doi:10.13188/2334-2838.1000014
Wu, L., Hernández-Bogantes, E., Roca, J. A., & Arévalo, J. F. (2012) · Retina · doi:10.1097/iae.0b013e31826e85c1
The Postvitrectomy Fibrin Response
Oh, D. J., & Modi, Y. S. (2022) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000422
siRNA-pallonukleiinihappojen synteesi silmänpohjan ikärappeuman hoitoon
Yliperttula, A.-M. (2025) · UTUPub (University of Turku)
Figurska, M., Matysik-Woźniak, A., Ręjdak, R., & Rękas, M. (2026) · Via Medica Journals
Metadata
- Authors
- Chong, D. Y., Anand, R., Williams, P. D., Qureshi, J. A., & Callanan, D. G.
- Affiliations
- Texas Retina Associates (United States) (US)
- Venue
- Retina
- Published
- 2010-10
- Volume
- 30
- Issue
- 9
- Pages
- 1432-1440
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2036940508
- Cited by
- 66
- References
- 14
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 4
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- bevacizumab, intravitreal injection, ranibizumab, recurrent inflammation, anti-VEGF therapy, visual acuity recovery
- MeSH terms
- Bevacizumab, Aged, Antibodies, Monoclonal, Female, Humans, Macular Degeneration, Macular Edema, Male, Endophthalmitis, Postoperative Complications, Retrospective Studies, Time Factors, Visual Acuity, Incidence, Retreatment, Recovery of Function, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.